VCAM-1 complements CA-125 in detecting recurrent ovarian cancer

Abstract

Background Close to three-quarters of ovarian cancer cases are frequently diagnosed at an advanced stage, with more than 70% of them failing to respond to primary therapy and relapsing within 5 years. There is an urgent need to identify strategies for early detection of ovarian cancer recurrence, which may lead to earlier intervention and better outcomes. Methods A customized magnetic bead-based 8-plex immunoassay was evaluated using a Bio-Plex 200 Suspension Array System. Target protein levels were analyzed in sera from 58 patients diagnosed with advanced ovarian cancer (including 34 primary and 24 recurrent tumors) and 46 healthy controls. The clinical performance of these biomarkers was evaluated individually and in combination for their ability to detect recurrent ovarian cancer. Results An 8-plex immunoassay was evaluated with high analytical performance suitable for biomarker validation studies. Logistic regression modeling selected a two-marker panel of CA-125 and VCAM-1 that improved the performance of CA-125 alone in detecting recurrent ovarian cancer (AUC: 0.813 versus 0.700). At a fixed specificity of 83%, the two-marker panel significantly improved sensitivity in separating primary from recurrent tumors (70.8% versus 37.5%, P = 0.004), demonstrating that VCAM-1 was significantly complementary to CA-125 in detecting recurrent ovarian cancer. Conclusions A two-marker panel of CA-125 and VCAM-1 showed strong diagnostic performance and improvement over the use of CA-125 alone in detecting recurrent ovarian cancer. The experimental results warrant further clinical validation to determine their role in the early detection of recurrent ovarian cancer.

Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis

“…VCAM1 [110], ADRB2 [126], and DAPK1 [183] might serve as genetic markers of endometriosis. The expression of VCAM1 [190], ADRB2 [237], FOXQ1 [210], ACTBL2 [357], DAPK1 [379], ACTC1 [359], CST4 [229], NFIB (nuclear factor I B) [363], NFIX (nuclear factor I X) [1657] and ERG (ETS transcription factor ERG) [1658] were altered in the ovarian cancer. VCAM1 [478], FOXQ1 [492], DAPK1 [609] and ERG (ETS transcription factor ERG) [1659] promotes the development of cervical cancer.…”

“…These analyses could help to find some miRNAs, TFs and hub genes involved in the regulation of endometriosis. CCND2 [246], VCAM1 [190], PDGFB (platelet derived growth factor subunit B) [221], PTCH1 [263], FOXQ1 [210], IGF2BP1 [324], ACTC1 [359], EPB41L3 [315], DAPK1 [379], hsa-mir-17-5p [1663], TCF3 [1664], RNF2 [1665], CLOCK (clock circadian regulator) [1666], SMARCA4 [1667] and TRIM28 [1668] provided a clear picture of the prognosis of patients with ovarian cancer. CCND2 [511], VCAM1 [478], PTCH1 [523], FOXQ1 [492], IGF2BP1 [568], EPB41L3 [560], DAPK1 [609], hsa-mir-17-5p [1669], TCF3 [1670] and TRIM28 [1671] as a biomarkers for cervical cancer.…”

“…In this investigation, we identified enriched genes in GO terms and signaling pathways that might be utilized as diagnostic and/or therapeutic targets in endometriosis. Signaling pathways include extracellular matrix organization [101], nervous system development [102], signal transduction [103], hemostasis [104], muscle contraction [105], signaling by retinoic acid [106] [189], VCAM1 [190], GRP (gastrin releasing peptide) [191], AQP8 [192], WNT6 [193], FABP4 [194], SOX6 [195], NTRK1 [196], CNTN1 [197], MMP12 [198], LAG3 [199], SOX18 [200], CCR1 [201], FLT1 [202], PRDM1 [203], TRPC3 [204], DKK2 [205], RNF157 [206], DHCR24 [207], BMP4 [208], PRL (prolactin) [209],…”